On this page
sulfacetamide sodium
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Sulfacetamide Sodium | 100 mg/mL | 832864 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Sulfonamide Antibacterial [EPC] | EPC | 6 members — no class page |
| Sulfonamides [CS] | CS | All 18 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 040066-001 | SULFACETAMIDE SODIUM | SOLUTION/DROPS | SULFACETAMIDE SODIUM | Prescription | AT | RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 12 | Manufacturing (CMC) | Approved | November 27, 2001 | — |
| Supplement | 11 | Manufacturing (CMC) | Approved | March 7, 2001 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | October 5, 2000 | — |
| Supplement | 9 | Manufacturing (CMC) | Approved | June 27, 2000 | — |
| Supplement | 6 | Manufacturing (CMC) | Approved | May 18, 2000 | — |
| Supplement | 8 | Manufacturing (CMC) | Approved | May 15, 2000 | — |
| Supplement | 7 | Manufacturing (CMC) | Approved | April 28, 2000 | — |
| Supplement | 5 | Manufacturing (CMC) | Approved | June 7, 1999 | — |
| Supplement | 4 | Manufacturing (CMC) | Approved | November 19, 1998 | — |
| Supplement | 3 | Manufacturing (CMC) | Approved | March 13, 1998 | — |
| Supplement | 1 | Manufacturing (CMC) | Approved | June 28, 1995 | — |
| Supplement | 2 | Manufacturing (CMC) | Approved | May 9, 1995 | — |
| Original application | 1 | Approved | December 28, 1994 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20240620). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Sulfacetamide Sodium Ophthalmic Solution, USP 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. Topically applied sulfonamides do not provide adequate coverage against Neisseria species, Serratia marcescens and Pseudomonas aeruginosa . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION For conjunctivitis and other superficial ocular infections: Instill one or two drops into the conjunctival sac(s) of the affected eye(s) every two to three hours initially. Dosages may be tapered by increasing the time interval between doses as the condition responds. The usual duration of treatment is seven to ten days. For trachoma: Instill two drops into the conjunctival sac(s) of the affected eye(s) every two hours. Topical administration must be accompanied by systemic administration.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Sulfacetamide Sodium Ophthalmic Solution, USP 10% is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.
Warnings
openFDA Drug LabelingWARNINGS FOR TOPICAL EYE USE ONLY - NOT FOR INJECTION. FATALITIES HAVE OCCURRED, ALTHOUGH RARELY, DUE TO SEVERE REACTIONS TO SULFONAMIDES INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, FULMINANT HEPATIC NECROSIS, AGRANULOCYTOSIS, APLASTIC ANEMIA AND OTHER BLOOD DYSCRASIAS. Sensitizations may recur when a sulfonamide is readministered, irrespective of the route of administration. Sensitivity reactions have been reported in individuals with no prior history of sulfonamide hypersensitivity. At the first sign of hypersensitivity, skin rash or other serious reaction, discontinue use of this preparation.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Bacterial and fungal corneal ulcers have developed during treatment with sulfonamide ophthalmic preparations. The most frequently reported reactions are local irritation, stinging and burning. Less commonly reported reactions include non-specific conjunctivitis, conjunctival hyperemia, secondary infections and allergic reactions. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias (see WARNINGS ). To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Drug Interactions
openFDA Drug LabelingDrug Interactions Sulfacetamide preparations are incompatible with silver preparations.
Description
openFDA Drug LabelingDESCRIPTION Sulfacetamide Sodium Ophthalmic Solution, USP 10% is a sterile, topical antibacterial agent for ophthalmic use. The active ingredient is represented by the following structural formula: C 8 H 9 N 2 NaO 3 S • H 2 O Mol. Wt. 254.24 Chemical name: N -Sulfanilylacetamide monosodium salt monohydrate. Each mL contains: ACTIVE: Sulfacetamide Sodium, 100 mg/mL (10%); INACTIVES: Methylcellulose, Purified Water, Sodium Thiosulfate. Sodium Phosphate Monobasic may be added to adjust pH (6.8 - 8.0). PRESERVATIVES ADDED: Methylparaben 0.05% and Propylparaben 0.01%. The osmolality range is 700-1300 mOsm/kg. Sulfacetamide Sodium (structural formula)
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Sulfacetamide Sodium Ophthalmic Solution, USP 10% is supplied in a plastic squeeze bottle with a controlled drop tip in the following size: NDC 71205-689-15 15 mL bottle Storage: Store between 2° to 25°C (36° to 77°F). Sulfonamide solutions, on long standing, will darken in color and should be discarded. Keep out of reach of children. Distributed by: Bausch + Lomb, a division of Bausch Health US, LLC Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA © 2020 Bausch & Lomb Incorporated or its affiliates Relabeled by: Proficient Rx LP Thousand Oaks, CA 91320 Revised: April 2020 do not use
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: SULFACETAMIDE SODIUM. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-0246-0 | 50090-0246 | A-S Medication Solutions | 1 BOTTLE, DROPPER in 1 CARTON (50090-0246-0) / 15 mL in 1 BOTTLE, DROPPER | June 29, 2016 |
| 76420-090-15 | 76420-090 | Asclemed USA, Inc. | 15 mL in 1 BOTTLE, DROPPER (76420-090-15) | October 24, 2020 |
| 24208-670-04 | 24208-670 | Bausch & Lomb Incorporated | 1 BOTTLE, DROPPER in 1 CARTON (24208-670-04) / 15 mL in 1 BOTTLE, DROPPER | December 28, 1994 |
| 68071-5123-5 | 68071-5123 | NuCare Pharmaceuticals,Inc. | 15 mL in 1 BOTTLE, DROPPER (68071-5123-5) | December 6, 2019 |
| 68788-9871-1 | 68788-9871 | Preferred Pharmaceuticals, Inc | 15 mL in 1 BOTTLE, DROPPER (68788-9871-1) | February 28, 2012 |
| 71205-689-15 | 71205-689 | Proficient Rx LP | 1 BOTTLE, DROPPER in 1 CARTON (71205-689-15) / 15 mL in 1 BOTTLE, DROPPER | August 26, 2022 |
| 50090-0246 | 50090-0246 | A-S Medication Solutions | — | December 28, 1994 |
| 76420-090 | 76420-090 | Asclemed USA, Inc. | — | December 28, 1994 |
| 24208-670 | 24208-670 | Bausch & Lomb Incorporated | — | December 28, 1994 |
| 68071-5123 | 68071-5123 | NuCare Pharmaceuticals,Inc. | — | December 28, 1994 |
| 68788-9871 | 68788-9871 | Preferred Pharmaceuticals, Inc | — | February 28, 2012 |
| 71205-689 | 71205-689 | Proficient Rx LP | — | December 28, 1994 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.